Evolutionary Genomics (Evolutionary Genomics) Cash-to-Debt : 0.15 (As of Dec. 2022)

View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Evolutionary Genomics's cash to debt ratio for the quarter that ended in Dec. 2022 was 0.15.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Evolutionary Genomics couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2022.

The historical rank and industry rank for Evolutionary Genomics's Cash-to-Debt or its related term are showing as below:

FNAM's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.39
* Ranked among companies with meaningful Cash-to-Debt only.

Evolutionary Genomics Cash-to-Debt Historical Data

The historical data trend for Evolutionary Genomics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Evolutionary Genomics Cash-to-Debt Chart

Evolutionary Genomics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

0.10

0.06

0.15

Evolutionary Genomics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Cash-to-Debt	Get a 7-Day Free Trial															0.06	0.28	0.24	0.21	0.15

Competitive Comparison of Evolutionary Genomics's Cash-to-Debt

For the Biotechnology subindustry, Evolutionary Genomics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolutionary Genomics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's Cash-to-Debt falls into.

Evolutionary Genomics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Evolutionary Genomics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.577	/	(0	+	3.744)
	=	0.15

Evolutionary Genomics's Cash to Debt Ratio for the quarter that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.577	/	(0	+	3.744)
	=	0.15

Evolutionary Genomics (OTCPK:FNAM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Evolutionary Genomics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolutionary Genomics (Evolutionary Genomics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

4220 Morning Star Drive, Castle Rock, CO, USA, 80108

Website

https://www.evolgen.com

Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.

Executives

Steve B Warnecke	director, 10 percent owner, officer: Chairman, CEO	C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff	director	4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier	officer: Secretary / Treasurer	1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess	director	7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz	director, 10 percent owner	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess	director, 10 percent owner, officer: President/CEO	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita	director, officer: Secretary/Treasurer/CFO	5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics (Evolutionary Genomics) Headlines

No Headlines